2025-11-07

Signet Therapeutics Wins BioTech Breakthrough Award For “Drug Discovery Innovation Award”

2025-04-01

Preclinical Data on SIGX1094R, the First Targeted Therapy for Diffuse Gastric Cancer, to be Presented at AACR 2025

2025-02-25

Expanded Access Policy

2025-01-21

World’s First Potential Target Therapy for Diffuse Gastric Cancer Granted Fast Track Designation by the U.S. FDA

2025-01-16

World’s First Drug Candidate developed by Organoid and AI Doses First Patient in Phase 1 Study for first Diffusive Gastric Cancer Targeted Therapy

2024-12-03

Signet Therapeutics Raised Over 9 Million US Dollars in Pre-A Round Funding to Accelerate Clinical Trials and Drug Development

2024-11-25

Signet Therapeutics Announces FDA Orphan Drug Designation (ODD) for SIGX1094R in Gastric Cancer Treatment

2024-09-20

Signet Therapeutics' Targeted Therapy for Diffuse Gastric Cancer Receives IND Accelerated Approval by the NMPA

2024-07-03

Signet Therapeutics Announces IND Approval by the FDA for World’s First Targeted Therapy for Diffuse Gastric Cancer